Compare Bristol-Myers Squibb Co (BMY) vs Lockheed Martin Corporation (LMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Lockheed Martin Corporation — how do they compare? Bristol-Myers Squibb Co trades at $58.34 (market cap $116.30B), while Lockheed Martin Corporation trades at $514.99 (market cap $118.74B). The key difference: Bristol-Myers Squibb Co and Lockheed Martin Corporation are close in size by market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | LMT | |
|---|---|---|
Market Cap | $116.30B | $118.74B |
Sector | Health | Industrials |
52-Week High | $62.37 | $676.70 |
52-Week Low | $42.60 | $410.74 |
Enterprise Value | $152.24B | $137.54B |
Dividend Yield | 4.42% | 2.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Lockheed Martin (LMT) trades at $520.68, down 0.49% on the day, with a bearish technical signal and mixed earnings history. The company reported $75.05B in 2025 revenue and a net income margin of 6.38%, while maintaining a $194B backlog as of Q4 2025 (24/7 Wall Street, 2026-07-13). Analyst consensus is bullish with a $614 price target, supported by strong defense spending trends.
Outlook remains positive due to robust demand from global defense budgets, but risks include execution challenges and margin pressure. The stock offers value with a P/E of 25.21 and dividend yield near 2.66%, though recent EPS misses warrant caution. Institutional sentiment favors long-term growth amid geopolitical tensions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →
